What does this research mean for the field?

Concurrent targeting of PI3K and IR/IGF-1R signaling synergistically overcomes adaptive resistance in PIK3CA-mutant non-small cell lung cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate the combined effects of targeting PI3K and IGFR pathways in lung cancer.

April 7, 2026Open Access

Synergistic effects through targeting the PI3K and IGFR pathways in treating lung cancer carrying activation alterations along the PI3K pathway

Key Points

The aim is to evaluate the combined effects of targeting PI3K and IGFR pathways in lung cancer.
Analyzed NSCLC cell lines with PIK3CA mutations.
Used inhibitors for both PI3K and IGFR pathways.
Observed cellular responses to therapy combinations.
Combination therapy effectively reduced cell growth.
Overcame resistance seen in PIK3CA-mutant cancers.
Supported further clinical evaluation for this strategy.

Abstract

Concurrent targeting of PI3K and IR/IGF-1R signaling effectively overcomes adaptive resistance in PIK3CA-mutant NSCLC, supporting the rationale for further clinical evaluation of this combined therapeutic strategy.

Synergistic effects through targeting the PI3K and IGFR pathways in treating lung cancer carrying activation alterations along the PI3K pathway

Key Points

Abstract

Cite This Study